-
公开(公告)号：US08853178B2
公开(公告)日：2014-10-07
申请号：US13177462
申请日：2011-07-06
Applicant: Sanjay Bhanot , Lex M. Cowsert , Jacqueline R. Wyatt , Brett P. Monia , Madelline M. Butler , Robert McKay , Susan M. Freier , Kenneth W. Dobie
Inventor： Sanjay Bhanot , Lex M. Cowsert , Jacqueline R. Wyatt , Brett P. Monia , Madelline M. Butler , Robert McKay , Susan M. Freier , Kenneth W. Dobie
IPC: C12N15/113
CPC classification number: C12N15/113 , A61K38/00 , A61K48/00 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12Y301/03048 , Y02P20/582 , C12N2310/3525
Abstract: Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.
Abstract translation: 提供化合物，组合物和方法用于调节PTP1B的表达。 组合物包含靶向编码PTP1B的核酸的反义化合物，特别是反义寡核苷酸。 提供了使用这些化合物调节PTP1B表达和治疗与PTP1B表达相关的疾病的方法。
-
公开(公告)号：US08673871B2
公开(公告)日：2014-03-18
申请号：US12299764
申请日：2007-05-07
Applicant: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
Inventor： Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
CPC classification number: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
Abstract translation: 本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。 因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。 此外，所述短反义化合物具有更大的口服给药潜力。
-
公开(公告)号：US08658783B2
公开(公告)日：2014-02-25
申请号：US13446763
申请日：2012-04-13
Applicant: Sanjay Bhanot , Susan M. Freier
Inventor： Sanjay Bhanot , Susan M. Freier
CPC classification number: C12N15/1137 , A61K31/7088 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3341 , C12N2310/34 , C12N2310/341 , C12N2310/346 , C12N2320/30 , C12Y301/03048 , C12N2310/3525
Abstract: Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
Abstract translation: 本文提供了用于降低动物体内PTP1B mRNA和蛋白质表达的方法，化合物和组合物。 这些方法，化合物和组合物可用于治疗，预防，延迟或改善代谢疾病，例如糖尿病或其症状。
-
公开(公告)号：US08586554B2
公开(公告)日：2013-11-19
申请号：US12299607
申请日：2007-05-07
Applicant: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
Inventor： Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
IPC: C12N15/11
CPC classification number: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
Abstract translation: 本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。 因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。 此外，所述短反义化合物具有更大的口服给药潜力。
-
公开(公告)号：US08362232B2
公开(公告)日：2013-01-29
申请号：US12883049
申请日：2010-09-15
Applicant: Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
Inventor： Sanjay Bhanot , Richard S. Geary , Robert McKay , Brett P. Monia , Punit P. Seth , Andrew M. Siwkowski , Eric E. Swayze , Edward Wancewicz
IPC: C07H21/04
CPC classification number: C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/341 , C12N2310/3515 , C12Y203/0102 , C12N2310/3521
Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
Abstract translation: 本公开描述了短反义化合物，包括长度为化学修饰的高亲和力单体8-16单体的这类化合物。 某些这样的短反义化合物可用于在增加的效力和改善的治疗指数的细胞，组织和动物中还原靶核酸和/或蛋白质。 因此，本文提供了包含用于在体内降低靶RNA的高亲和力核苷酸修饰的短反义化合物。 这样的短反义化合物在比以前描述的反义化合物低的剂量下是有效的，允许降低毒性和治疗成本。 此外，所述短反义化合物具有更大的口服给药潜力。
-
Patent Agency Ranking
公开(公告)号：US08299041B2
公开(公告)日：2012-10-30
申请号：US11910606
申请日：2006-04-10
Applicant: Sanjay Bhanot , Brett P. Monia , John G. Geisler , Robert McKay , Kenneth W. Dobie
Inventor： Sanjay Bhanot , Brett P. Monia , John G. Geisler , Robert McKay , Kenneth W. Dobie
IPC: A61K48/00
CPC classification number: C12N15/1137 , A61K31/202 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3521
Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of ACC1 or ACC2 or both in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
Abstract translation: 本文公开了用于在细胞，组织或动物中调节ACC1或ACC2或两者的表达的化合物，组合物和方法。 还提供了所公开的化合物和组合物在制备用于治疗疾病和病症的药物中的用途。
-
公开(公告)号：US08258114B2
公开(公告)日：2012-09-04
申请号：US13045187
申请日：2011-03-10
Applicant: Sanjay Bhanot
Inventor： Sanjay Bhanot
CPC classification number: C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3525
Abstract: Compositions and methods are provided for decreasing blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of glucose-6-phosphatase translocase expression alone or in combination with at least one glucose-lowering drug. Also provided are compositions and methods for treating diabetes and other metabolic disorders.
Abstract translation: 提供了用于降低动物体内血糖水平的组合物和方法，其包括向所述动物施用单独的葡萄糖-6-磷酸酶转位酶表达的反义抑制剂或与至少一种葡萄糖降低药物组合。 还提供了用于治疗糖尿病和其它代谢紊乱的组合物和方法。
-
公开(公告)号：US20120077865A1
公开(公告)日：2012-03-29
申请号：US13302070
申请日：2011-11-22
Applicant: Susan M. FREIER , Rosanne M. Crooke , Mark J. Graham , Kristina M. Lemonidis , Sanjay Bhanot , Diane Tribble , Andrew T. Watt
Inventor： Susan M. FREIER , Rosanne M. Crooke , Mark J. Graham , Kristina M. Lemonidis , Sanjay Bhanot , Diane Tribble , Andrew T. Watt
IPC: A61K31/713 , A61P7/00 , A61P3/06 , A61P9/10 , A61P3/10 , A61P1/16 , A61P3/00 , C07H21/04 , A61P9/00
CPC classification number: C12N15/1137 , A61K45/06 , A61K48/00 , C12N2310/11 , C12N2310/321 , C12N2310/351 , C12N2320/30
Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
Abstract translation: 本文公开了用于降低具有升高的LDL-C的个体中的LDL-C的反义化合物和方法。 另外公开了用于治疗，预防或改善高胆固醇血症和/或动脉粥样硬化的反义化合物和方法。 进一步公开的是用于降低冠心病风险的反义化合物和方法。 这样的方法包括向需要治疗的个体施用靶向PCSK9核酸的反义化合物。 施用的反义化合物包括gapmer反义寡核苷酸。
-
9.发明申请公开(公告)号：US20120029050A1
公开(公告)日：2012-02-02
申请号：US13177457
申请日：2011-07-06
Applicant: Xing-Xian Yu , Sanjay Bhanot , Brett P. Monia
Inventor： Xing-Xian Yu , Sanjay Bhanot , Brett P. Monia
IPC: A61K31/713 , A61P1/16
CPC classification number: C12N15/1137 , C12N2310/11 , C12Y203/0102
Abstract: Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator.
Abstract translation: 本文公开了用于调节DGAT-1活性的化合物，组合物和方法。 优选地，来自核酸的DGAT-1的表达被抑制。 提供了直接治疗或改善肝纤维化或通过治疗潜在病因的方法。 优选地，治疗，改善或预防包括施用DGAT-1活性调节剂。
-
公开(公告)号：US08101585B2
公开(公告)日：2012-01-24
申请号：US11834672
申请日：2007-08-06
Applicant: Xing-Xian Yu , Sanjay Bhanot
Inventor： Xing-Xian Yu , Sanjay Bhanot
CPC classification number: A61K31/07 , C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/3525
Abstract: The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein.
Abstract translation: 本发明提供了用于治疗和诊断适于通过调节编码JunN-末端激酶1（JNK1蛋白）的基因的表达进行治疗的疾病或病症的组合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
113
records
(took 0.086 seconds)
